Epidermal growth factor-urogastrone receptors in normal human liver and primary hepatoma.
Epidermal growth factor-urogastrone (EGF-URO) receptors have been demonstrated in rodent liver and modulation of ligand binding during transformation has been shown in a variety of study systems. A patient presented with a resectable primary hepatoma arising in a histologically normal liver. We carried out ligand binding studies using 125I-EGF and homogenates or plasma membrane preparations of normal and hepatoma tissues. EGF-URO receptors were demonstrated in normal human liver; half-maximal binding occurred at 2.5 X 10(-9) M 125I-EGF. Binding decreased in association with hepatoma formation. These results provide initial evidence that EGF-URO receptors exist in human liver and that ligand binding changes accompany hepatoma formation in man.
D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D066246:ErbB Receptors; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D011869:Radioligand Assay; D011956:Receptors, Cell Surface / Q000032:analysis*
D011956:Receptors, Cell Surface; D066246:ErbB Receptors